# A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

> **NCT04607421** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 831 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Encorafenib
- **DRUG:** Cetuximab
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-FU
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04607421
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-21
- **Primary completion:** 2025-12-08
- **Final completion:** 2027-12-28
- **Target enrollment:** 831 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607421, "A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04607421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*